Trial Profile

Evaluation of the Safety, Pharmacokinetics and Efficacy of Three Doses of YN968D1 in Subjects With Solid Tumors.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivoceranib (Primary)
Indications Breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions
Sponsors Elevar Therapeutics

Most Recent Events

11 Oct 2016 Results assessing preliminary efficacy and safety of apatinib in advanced solid tumors (n=30) presented at the 41st European Society for Medical Oncology Congress.
02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
13 May 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com